Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Gains from Investment Securities (2024 - 2025)

Bioharvest Sciences has reported Gains from Investment Securities over the past 2 years, most recently at -$360000.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 95.82% year-over-year to -$360000.0; the TTM value through Dec 2025 reached -$9.0 million, changed N/A, while the annual FY2025 figure was $39000.0, 13.33% down from the prior year.
  • Gains from Investment Securities was -$360000.0 for Q4 2025 at Bioharvest Sciences, up from -$8.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at -$360000.0 in Q4 2025 and bottomed at -$8.6 million in Q4 2024.